<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911114-0071</DOCNO><DOCID>911114-0071.</DOCID><HL>   Technology:   Isis Pharmaceuticals Agreement</HL><DATE>11/14/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   ISIP</CO><MS>TECHNOLOGY (TEC)</MS><IN>MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>LICENSING AGREEMENTS (LIC)</NS><RE>CALIFORNIA (CA)NORTH CAROLINA (NC)NORTH AMERICA (NME)PACIFIC RIM (PRM)UNITED STATES (US)</RE><LP>   CARLSBAD, Calif. -- Isis Pharmaceuticals Inc. said itentered into an option agreement with the University of NorthCarolina at Chapel Hill to license a synthetic geneticmolecule used to treat Epstein-Barr viral infections.   In return for the option, which lasts 18 months, Isis willapply for and pay the costs of a patent for the moleculartreatment, which was invented by Joseph Pagano and othermembers of his laboratory at the university's LinebergerCancer Center, the company said. Dr. Pagano has beencollaborating with Isis scientists for more than a year.</LP><TEXT>   Isis develops and markets human therapeutic products basedon so-called anti-sense technology, which involves blockingthe &quot;sense&quot; function of genetic material.</TEXT></DOC>